Home › Funds › UBS Group AG › PCVX
UBS Group AG position in PCVX
VAXCYTE INC · Health Care
Latest position (Q2 2026)776.51K sh
Reported value held$45.14M
Portfolio Weight0.01%
First reportedQ3 2021
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2021 | 121.79K | $3.09M | New |
| Q4 2021 | 45.23K | $1.08M | Reduce |
| Q1 2022 | 60.39K | $1.46M | Add |
| Q2 2022 | 23.57K | $513.00K | Reduce |
| Q3 2022 | 75 | $2.00K | Reduce |
| Q4 2022 | 122.72K | $5.88M | Add |
| Q1 2023 | 344 | $12.89K | Reduce |
| Q2 2023 | 45.82K | $2.29M | Add |
| Q3 2023 | 74.31K | $3.79M | Add |
| Q4 2023 | 166.03K | $10.43M | Add |
| Q1 2024 | 176.08K | $12.03M | Add |
| Q2 2024 | 95.68K | $7.22M | Reduce |
| Q3 2024 | 111.57K | $12.75M | Add |
| Q4 2024 | 736.56K | $60.29M | Add |
| Q1 2025 | 1.08M | $40.80M | Add |
| Q2 2025 | 1.38M | $44.89M | Add |
| Q3 2025 | 847.57K | $30.53M | Reduce |
| Q4 2025 | 1.09M | $50.46M | Add |
| Q1 2026 | 1.34M | $77.72M | Add |
| Q2 2026 | 776.51K | $45.14M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding PCVX
- Fidelity Management & Research (FMR) 20.85M sh · $1.21B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- BlackRock Inc 12.07M sh · $701.52M · Q2 2026
- Vanguard Group 12.19M sh · $562.63M · Q4 2025
- Wellington Management Group 7.00M sh · $407.00M · Q2 2026
- Geode Capital Management 3.46M sh · $201.13M · Q2 2026
- D. E. Shaw & Co 1.90M sh · $110.56M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- Charles Schwab Investment Management 1.46M sh · $85.15M · Q2 2026
- Goldman Sachs Group 1.38M sh · $79.98M · Q2 2026
- Northern Trust Corp 1.28M sh · $74.42M · Q2 2026
- Norges Bank Investment Management 1.25M sh · $72.42M · Q2 2026